Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP an...
Aedifica reports 1H25 results in line with our estimates at EUR 123.3m EPRA earnings vs EUR 122.2m KBCSe. It confirms its outlook at EUR 5.01 EPRA EPS despite being slightly ahead of its guidance. YTD (30/07) Aedifica refuelled its development pipeline at 6.5% YoC by EUR 84m (Finland, UK) and divested EUR 121m (32 properties, mainly Sweden), completed EUR 66m projects and did one acquisition of EUR 37.5m. The eyes of the market are on the potential Aedifica/Cofinimmo combination. It is largely s...
Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...
Aedifica NV/SA: 2025 half year financial report Please find below Aedifica’s 2025 half year financial report. Robust operational performance driving strong results EPRA Earnings* amounted to €123.3 million (+4% compared to 30 June 2024), or €2.59/shareRental income increased to €180.8 million (+9% compared to 30 June 2024)3.0% increase in rental income on a like-for-like basis in the first half of the yearWeighted average unexpired lease term of 18 years and occupancy rate of 100% Real estate portfolio* of nearly €6.2 billion as at 30 June 2025 613 healthcare properties for 48,600 end u...
Aalberts reports the progress of its share buyback programme 21 July – 25 July 2025 Utrecht, 29 July 2025, Aalberts today reports that it has repurchased 145,500 of its own shares in the period from 21 July 2025, up to and including 25 July 2025, for an amount of EUR 4,011,589.94, so at an average share price of EUR 27.57. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancel...
MaaT announced that it has secured a € 37.5m , 4-tranche financing from the European Investment Bank (EIB), which bears interest at 7%. In addition, MaaT will issue warrants to the EIB with each tranche. MaaT's previously communicated cash runway was into January 2026, which should now extend beyond that point following this additional funding, though we do note that disbursement of Tranches B to D is subject to operational and financing conditions, which we'd be keen to learn more about. All in...
Last Thursday, Aalberts reported 1H25 results that fell short of expectations. Management no longer anticipates a recovery in growth during 2H25 and now guides for a full-year EBITA margin of 13–14% (previously >15%). The 2026 margin target of 16–18% was not reaffirmed. As a result, the stock sharply declined, erasing all gains since the announcement of its intention to acquire the listed Singaporean mechatronics company GVT. Despite the disappointing update, we maintain our Accumulate rating on...
This morning Aalberts reported 1H25 numbers. Building continued to show a minimal organic growth in 2Q (as in 4Q and 1Q). In Industry the topline decline slowed down to -2.9% and margins benefitted from footprint and cost out initiatives (+90bps q/q). Semicon suffered from an acceleration in the growth decline to -15.5% (2Q) from -11.3% (1Q). Overall, management no longer banks on a growth recovery in 2H25 and expects full year margins to be at 13-14% (previously > 15%). 2026 margin targets (16-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.